AAAAAA

   
Results: 1-11 |
Results: 11
Synthesis and biological evaluation of O-alkylated tropolones and related alpha-ketohydroxy derivatives as ribonucleotide reductase inhibitors
Authors: Tamburlin-Thumin, I Crozet, MP Barriere, JC Barreau, M Riou, JF Lavelle, F
Citation: I. Tamburlin-thumin et al., Synthesis and biological evaluation of O-alkylated tropolones and related alpha-ketohydroxy derivatives as ribonucleotide reductase inhibitors, EUR J MED C, 36(6), 2001, pp. 561-568
From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase
Authors: Mailliet, P Laoui, A Bourzat, JD Capet, M Cheve, M Commercon, A Dereu, N LeBrun, A Martin, JP Peyronel, JF Salagnad, C Thompson, F Zucco, M Guitton, JD Pantel, G Bissery, MC Brealey, C Lavayre, J Lelievre, Y Riou, JF Vrignaud, P Duchesne, M Lavelle, F
Citation: P. Mailliet et al., From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase, CANC DRUG, 8, 2001, pp. 115-144
Telomerase: a therapeutic target for the third millennium?
Authors: Lavelle, F Riou, JF Laoui, A Mailliet, P
Citation: F. Lavelle et al., Telomerase: a therapeutic target for the third millennium?, CR R ONC H, 34(2), 2000, pp. 111-126
RPR112378 and RPR115781: Two representatives of a new family of microtubule assembly inhibitors
Authors: Combeau, C Provost, J Lancelin, F Tournoux, Y Prod'homme, F Herman, F Lavelle, F Leboul, J Vuilhorgne, M
Citation: C. Combeau et al., RPR112378 and RPR115781: Two representatives of a new family of microtubule assembly inhibitors, MOLEC PHARM, 57(3), 2000, pp. 553-563
Multivariate data analysis using D-optimal designs, partial least squares,and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors
Authors: Giraud, E Luttmann, C Lavelle, F Riou, JF Mailliet, P Laoui, A
Citation: E. Giraud et al., Multivariate data analysis using D-optimal designs, partial least squares,and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors, J MED CHEM, 43(9), 2000, pp. 1807-1816
Untitled
Authors: Lavelle, F
Citation: F. Lavelle, Untitled, B CANCER, 87(11), 2000, pp. 776-776
Purification and characterization of human DNA topoisomerase III alpha
Authors: Goulaouic, H Roulon, T Flamand, O Grondard, L Lavelle, F Riou, JF
Citation: H. Goulaouic et al., Purification and characterization of human DNA topoisomerase III alpha, NUCL ACID R, 27(12), 1999, pp. 2443-2450
The development of telomerase inhibitors: the G-quartet approach
Authors: Mergny, JL Mailliet, P Lavelle, F Riou, JF Laoui, A Helene, C
Citation: Jl. Mergny et al., The development of telomerase inhibitors: the G-quartet approach, ANTI-CAN DR, 14(4), 1999, pp. 327-339
Domain-structured N-1,N-2-derivatized hydrazines as inhibitors of ribonucleoside diphosphate reductase: Redox-cycling considerations
Authors: Sarel, S Fizames, C Lavelle, F Avramovici-Grisaru, S
Citation: S. Sarel et al., Domain-structured N-1,N-2-derivatized hydrazines as inhibitors of ribonucleoside diphosphate reductase: Redox-cycling considerations, J MED CHEM, 42(2), 1999, pp. 242-248
`Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells
Authors: Mazet, JL Padieu, M Osman, H Maume, G Mailliet, P Dereu, N Hamilton, AD Lavelle, F Sebti, SM Maume, BF
Citation: Jl. Mazet et al., `Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells, FEBS LETTER, 460(2), 1999, pp. 235-240
New anticancer chemicals: Drugs of tomorrow
Authors: Lavelle, F
Citation: F. Lavelle, New anticancer chemicals: Drugs of tomorrow, B CANCER, 86(1), 1999, pp. 91-95
Risultati: 1-11 |